RHOT1 and Parkinson disease: Furthermore, Miro degradation was shown to be impaired in PD patients' derived fibroblasts (Hsieh et al, 2016) and several Miro1 mutations have been identified as risk factors in patients with PD, further supporting the involvement of Miro1 in the pathogenesis of the disease (Berenguer‐Escuder et al, 2019; Grossmann et al, 2019; Berenguer‐Escuder et al, 2020).